From CFTR biology toward combinatorial pharmacotherapy: Expanded classification of cystic fibrosis mutations

Molecular Biology of the Cell

Volumn 27, Issue 3, 2016, Pages 424-433

  Veit, Gudio ^a   Avramescu, Radu G ^a   Chiang, Annette N ^c   Houck, Scott A ^d   Cai, Zhiwei ^e   Peters, Kathryn W ^f   Hong, Jeong S ^g   Pollard, Harvey B ^h   Guggino, William B ^a   Balch, William E ^l   Skach, William R ^k   Cutting, Garry R ^i,j   Frizzell, Raymon A ^f   Sheppard, David N ^e   Cyr, Douglas M ^d   Sorscher, Eric J ^l   Brodsky, Jeffrey L ^c   Lukacs, Gergely L ^a,b  

^a Department of Physiology ^*  (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j SCRIPPS RESEARCH INSTITUTE   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; CFTR PROTEIN, HUMAN; CHLORIDE CHANNEL STIMULATING AGENT;

ARTICLE; CHLORIDE CONDUCTANCE; CYSTIC FIBROSIS; DISEASE SEVERITY; FOOD AND DRUG ADMINISTRATION; HUMAN; MOLECULAR PATHOLOGY; NONSENSE MUTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; AGONISTS; ANIMAL; CHANNEL GATING; CLASSIFICATION; GENETIC PREDISPOSITION; GENETICS; MISSENSE MUTATION;

ANIMALS; CHLORIDE CHANNEL AGONISTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ION CHANNEL GATING; MUTATION, MISSENSE;

EID: 84956613592     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E14-04-0935     Document Type: Article

References (94)

1. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, et al. (2010). Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363, 1991-2003.
2. Awatade NT, Uliyakina I, Farinha CM, Clarke LA, Mendes K, Sole A, Pastor J, Ramos MM, Amaral MD (2015). Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine 2, 147-153.
3. Barr HL, Britton J, Smyth AR, Fogarty AW (2011). Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. Br Med J 343, d4662.
4. Bompadre SG, Sohma Y, Li M, Hwang TC (2007). G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J Gen Physiol 129, 285-298.
5. Boucher RC (2007). Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 58, 157-170.
6. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D (2014). A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: A phase 2 randomised controlled trial. Lancet Respir Med 2, 527-538.
7. Caldwell RA, Grove DE, Houck SA, Cyr DM (2011). Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators. Am J Physiol Lung Cell Mol Physiol 301, L346-L352.
8. Char JE, Wolfe MH, Cho HJ, Park IH, Jeong JH, Frisbee E, Dunn C, Davies Z, Milla C, Moss RB, et al. (2014). A little CFTR goes a long way: CFTRdependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor. PLoS One 9, e88564.
9. Chen JH, Stoltz DA, Karp PH, Ernst SE, Pezzulo AA, Moninger TO, Rector MV, Reznikov LR, Launspach JL, Chaloner K, et al. (2010). Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143, 911-923.
10. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63, 827-834.
11. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al. (2012). Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12-18.
12. Collaco JM, Cutting GR (2008). Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med 14, 559-566.
13. Collins FS (1992). Cystic fibrosis: molecular biology and therapeutic implications. Science 256, 774-779.
14. Cushing PR, Vouilleme L, Pellegrini M, Boisguerin P, Madden DR (2010). A stabilizing influence: CAL PDZ inhibition extends the half-life of δF508- CFTR. Angew Chem Int Ed Engl 49, 9907-9911.
15. Cutting GR (2010). Modifier genes in Mendelian disorders: The example of cystic fibrosis. Ann NY Acad Sci 1214, 57-69.
16. Cutting GR (2015). Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 16, 45-56.
17. Cyr DM (2005). Arrest of CFTR δF508 folding. Nat Struct Mol Biol 12, 2-3.
18. Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, Lazdunski M (1991). Altered chloride ion channel kinetics associated with the δF508 cystic fibrosis mutation. Nature 354, 526-528.
19. Derichs N, Jin BJ, Song Y, Finkbeiner WE, Verkman AS (2011). Hyperviscous airway periciliary and mucous liquid layers in cystic fibrosis measured by confocal fluorescence photobleaching. FASEB J 25, 2325-2332.
20. Du K, Lukacs GL (2009). Cooperative assembly and misfolding of CFTR domains in vivo. Mol Biol Cell 20, 1903-1915.
21. Du K, Sharma M, Lukacs GL (2005). The δF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 12, 17-25.
22. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM (2008). PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 105, 2064-2069.
23. Fanen P, Labarthe R, Garnier F, Benharouga M, Goossens M, Edelman A (1997). Cystic fibrosis phenotype associated with pancreatic insufficiency does not always reflect the cAMP-dependent chloride conductive pathway defect. Analysis of C225R-CFTR and R1066C-CFTR. J Biol Chem 272, 30563-30566.
24. Farinha CM, King-Underwood J, Sousa M, Correia AR, Henriques BJ, Roxo-Rosa M, Da Paula AC, Williams J, Hirst S, Gomes CM, Amaral MD (2013). Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol 20, 943-955.
25. Farrell PM (2008). The prevalence of cystic fibrosis in the European Union. J Cyst Fibros 7, 450-453.
26. Faucz FR, Gimenez J, Ramos MD, Pereira-Ferrari L, Estivill X, Raskin S, Casals T, Culpi L (2007). Cystic fibrosis in a southern Brazilian population: characteristics of 90% of the alleles. Clin Genet 72, 218-223.
27. Fu L, Rab A, Tang L, Bebok Z, Rowe SM, Bartoszewski R, Collawn JF (2015). δF508 CFTR surface stability is regulated by DAB2 and CHIP-mediated ubiquitination in post-endocytic compartments. PLoS One 10, e0123131.
28. Gentzsch M, Aleksandrov A, Aleksandrov L, Riordan JR (2002). Functional analysis of the C-terminal boundary of the second nucleotide binding domain of the cystic fibrosis transmembrane conductance regulator and structural implications. Biochem J 366, 541-548.
29. Haardt M, Benharouga M, Lechardeur D, Kartner N, Lukacs GL (1999). C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem 274, 21873-21877.
30. Hammerle MM, Aleksandrov AA, Riordan JR (2001). Disease-associated mutations in the extracytoplasmic loops of cystic fibrosis transmembrane conductance regulator do not impede biosynthetic processing but impair chloride channel stability. J Biol Chem 276, 14848-14854.
31. Hamosh A, Rosenstein BJ, Cutting GR (1992). CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum Mol Genet 1, 542-544.
32. Harness-Brumley C, Millen L, Huerta C, Schmidt A, Wigley W, Sosnay PR, Cutting GR, Thomas PJ (2014). Groups of Cftr2 disease-causing mutations that respond to specific modulators. Pediatr Pulmonol 49, 220-220.
33. He L, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, Riordan JR (2013). Correctors of δF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J 27, 536-545.
34. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A, Gorvoy JD, Quittel L, Friedman KJ, Silverman LM, et al. (1994). A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331, 974-980.
35. Highsmith WE Jr., Burch LH, Zhou Z, Olsen JC, Strong TV, Smith T, Friedman KJ, Silverman LM, Boucher RC, Collins FS, Knowles MR (1997). Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum Mutat 9, 332-338.
36. Hong JS, Mahiou J, Liang F, Bihler HJ, Mense M, Lukacs GL, Wen H, Sorscher EJ (2014). Epithelial models encoding diverse Cftr2 mutations for studies of disease mechanism and drug discovery. Pediatr Pulmonol 49, 277-278.
37. Hutt DM, Herman D, Rodrigues AP, Noel S, Pilewski JM, Matteson J, Hoch B, Kellner W, Kelly JW, Schmidt A, et al. (2010). Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 6, 25-33.
38. Ivaschenko TE, Baranov VS, Dean M (1993). Two new mutations detected by single-strand conformation polymorphism analysis in cystic fibrosis from Russia. Hum Genet 91, 63-65.
39. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, et al. (2014). Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2, 539-547.
40. Kerr ID (2002). Structure and association of ATP-binding cassette transporter nucleotide-binding domains. Biochim Biophys Acta 1561, 47-64.
41. Kim SJ, Skach WR (2012). Mechanisms of CFTR Folding at the endoplasmic reticulum. Front Pharmacol 3, 201.
42. Kopp BT, Sarzynski L, Khalfoun S, Hayes D Jr., Thompson R, Nicholson L, Long F, Castile R, Groner J (2015). Detrimental effects of secondhand smoke exposure on infants with cystic fibrosis. Pediatr Pulmonol 50, 25-34.
43. Lentini L, Melfi R, Di Leonardo A, Spinello A, Barone G, Pace A, Palumbo Piccionello A, Pibiri I (2014). Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: A computational approach and GFP-reporter cell-based assay. Mol Pharm 11, 653-664.
44. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, Kerem B (2007). Nonsensemediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 117, 683-692.
45. Loo TW, Bartlett MC, Clarke DM (2013). Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Biochem Pharmacol 86, 612-619.
46. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M, Guido S, Pettoello-Mantovani M, Carnuccio R, Scholte B, et al. (2012). Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on δF508 cystic fibrosis transmembrane conductance regulator. Autophagy 8, 1657-1672.
47. Lukacs GL, Chang XB, Bear C, Kartner N, Mohamed A, Riordan JR, Grinstein S (1993). The δF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem 268, 21592-21598.
48. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S (1994). Conformational maturation of CFTR but not its mutant counterpart (?F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 13, 6076-6086.
49. Mendoza JL, Schmidt A, Li Q, Nuvaga E, Barrett T, Bridges RJ, Feranchak AP, Brautigam CA, Thomas PJ (2012). Requirements for efficient correction of δF508 CFTR revealed by analyses of evolved sequences. Cell 148, 164-174.
50. Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M (2015). Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A doubleblind, randomised controlled trial. Lancet Respir Med 3, 524-533.
51. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, Hohfeld J, Young JC, Lukacs GL (2010). Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805-810.
52. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, et al. (2013). Mechanism-based corrector combination restores ?F508-CFTR folding and function. Nat Chem Biol 9, 444-454.
53. Pedemonte N, Tomati V, Sondo E, Galietta LJ (2010). Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298, C866-C874.
54. Pettit RS, Fellner C (2014). CFTR modulators for the treatment of cystic fibrosis. P T 39, 500-511.
55. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, Karp PH, Wohlford-Lenane CL, Haagsman HP, van Eijk M, et al. (2012). Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 487, 109-113.
56. Rabeh WM, Bossard F, Xu H, Okiyoneda T, Bagdany M, Mulvihill CM, Du K, di Bernardo S, Liu Y, Konermann L, et al. (2012). Correction of both NBD1 energetics and domain interface is required to restore δF508 CFTR folding and function. Cell 148, 150-163.
57. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365, 1663-1672.
58. Rapino D, Sabirzhanova I, Lopes-Pacheco M, Grover R, Guggino WB, Cebotaru L (2015). Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation. PLoS One 10, e0119796.
59. Ratjen F, Doring G (2003). Cystic fibrosis. Lancet 361, 681-689.
60. Ren HY, Grove DE, De La Rosa O, Houck SA, Sopha P, Van Goor F, Hoffman BJ, Cyr DM (2013). VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 24, 3016-3024.
61. Riordan JR (1993). The cystic fibrosis transmemebrane conductance regulator. Annu Rev Physiol 55, 609-630.
62. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. (1989). Identification of thecystic fibrosis gene: cloning and characterization of complementary DNA. Science 245, 1066-1073.
63. Rowe SM, Miller S, Sorscher EJ (2005). Cystic fibrosis. N Engl J Med 352, 1992-2001.
64. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC (2001). The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med 163, 1331-1337.
65. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, et al. (2010). Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 182, 1262-1272.
66. Sheppard DN, Ostedgaard LS, Winter MC, Welsh MJ (1995). Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. EMBO J 14, 876-883.
67. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ (1993). Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties. Nature 362, 160-164.
68. Sheppard DN, Travis SM, Ishihara H, Welsh MJ (1996). Contribution of proline residues in the membrane-spanning domains of cystic fibrosis transmembrane conductance regulator to chloride channel function. J Biol Chem 271, 14995-15001.
69. Silvis MR, Picciano JA, Bertrand C, Weixel K, Bridges RJ, Bradbury NA (2003). A mutation in the cystic fibrosis transmembrane conductance regulator generates a novel internalization sequence and enhances endocytic rates. J Biol Chem 278, 11554-11560.
70. Sosnay PR, Siklosi KR, Van Goor F, Kaniecki K, Yu H, Sharma N, Ramalho AS, Amaral MD, Dorfman R, Zielenski J, et al. (2013). Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet 45, 1160-1167.
71. Stoltz DA, Meyerholz DK, Welsh MJ (2015). Origins of cystic fibrosis lung disease. N Engl J Med 372, 351-362.
72. Tarran R, Grubb BR, Parsons D, Picher M, Hirsh AJ, Davis CW, Boucher RC (2001). The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 8, 149-158.
73. Taylor-Robinson DC, Thielen K, Pressler T, Olesen HV, Diderichsen F, Diggle PJ, Smyth R, Whitehead M (2014). Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population. Eur Respir J 44, 1363-1366.
74. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106, 18825-18830.
75. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108, 18843-18848.
76. Van Goor F, Yu H, Burton B, Hoffman BJ (2014). Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 13, 29-36.
77. Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, Borot F, Szollosi D, Wu YS, Finkbeiner WE, et al. (2014). Some gating potentiators, including VX-770, diminish δF508-CFTR functional expression. Sci Transl Med 6, 246-97.
78. Vertex (2014a). U.S. Food and Drug Administration approves KALYDECO™ (ivacaftor) for use in eight additional mutations that cause cystic fibrosis. Press release, February 21, 2014. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=827435 (accessed 1 October 2015).
79. Vertex (2014b). U.S. Food and Drug Administration approves KALYDECO® (ivacaftor) for use in people with cystic fibrosis ages 6 and older who have the R117H Mutation. Press release, December 29, 2014. http://investors.vrtx.com/releasedetail.cfm?ReleaseIDδ889027 (accessed 1 October 2015).
80. Vertex (2015). FDA approves ORKAMBI™ (lumacaftor/ivacaftor)-the first medicine to treat the underlying cause of cystic fibrosis for people ages 12 and older with two copies of the F508del mutation. Press release, July 2, 2015. http://investors.vrtx.com/releasedetail.cfm?ReleaseIDδ920512 (accessed 1 October 2015).
81. Visca A, Bishop CT, Hilton SC, Hudson VM (2008). Improvement in clinical markers in CF patients using a reduced glutathione regimen: An uncontrolled, observational study. J Cyst Fibros 7, 433-436.
82. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, et al. (2015).Lumacaftor- ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373, 220-231.
83. Wang Y, Liu J, Loizidou A, Bugeja LA, Warner R, Hawley BR, Cai Z, Toye AM, Sheppard DN, Li H (2014). CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR. Br J Pharmacol 171, 4490-4503.
84. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, et al. (2007). PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87-91.
85. Welsh MJ, Smith AE (1993). Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73, 1251-1254.
86. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, et al. (2011). Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38, 59-69.
87. Xue X, Mutyam V, Tang L, Biswas S, Du M, Jackson LA, Dai Y, Belakhov V, Shalev M, Chen F, et al. (2014). Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol 50, 805-816.
88. Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, Pedemonte N, et al. (2003). Nanomolar affinity small moleculecorrectors of defective δF508-CFTR chloride channel gating. J Biol Chem 278, 35079-35085.
89. Yang Y, Devor DC, Engelhardt JF, Ernst SA, Strong TV, Collins FS, Cohn JA, Frizzell RA, Wilson JM (1993). Molecular basis of defective anion transport in L cells expressing recombinant forms of CFTR. Hum Mol Genet 2, 1253-1261.
90. Yousef S, Solomon GM, Brody A, Rowe SM, Colin AA (2015). Improved clinical and radiographic outcomes after treatment with ivacaftor in a young adult with cystic fibrosis with the P67L CFTR mutation. Chest 147, e79-e82.
91. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr., Urrutia A, Joubran J, Seepersaud S, Sussky K, Hoffman BJ, Van Goor F (2012). Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros 11, 237-245.
92. Yu YC, Miki H, Nakamura Y, Hanyuda A, Matsuzaki Y, Abe Y, Yasui M, Tanaka K, Hwang TC, Bompadre SG, Sohma Y (2011). Curcumin and genistein additively potentiate G551D-CFTR. J Cyst Fibros 10, 243-252.
93. Zielenski J (2000). Genotype and phenotype in cystic fibrosis. Respiration 67, 117-133.
94. Zielenski J, Tsui LC (1995). Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 29, 777-807.